[go: up one dir, main page]

PE20240825A1 - Anticuerpos anti-c5 y metodos de uso - Google Patents

Anticuerpos anti-c5 y metodos de uso

Info

Publication number
PE20240825A1
PE20240825A1 PE2023002969A PE2023002969A PE20240825A1 PE 20240825 A1 PE20240825 A1 PE 20240825A1 PE 2023002969 A PE2023002969 A PE 2023002969A PE 2023002969 A PE2023002969 A PE 2023002969A PE 20240825 A1 PE20240825 A1 PE 20240825A1
Authority
PE
Peru
Prior art keywords
antibodies
seq
beta chain
epitope
domain
Prior art date
Application number
PE2023002969A
Other languages
English (en)
Inventor
Yoshinao Ruike
Zenjiro Sampei
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20240825A1 publication Critical patent/PE20240825A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion refiere a anticuerpos anti-C5, los cuales se unen a un epitopo dentro de la cadena beta (SEQ ID NO: 40) de C5 con una mayor afinidad a pH neutro que a pH acido. Dichos anticuerpos se unen a un epitopo dentro del dominio MG1-MG2 de la cadena beta (SEQ ID NO: 40) de C5, la cual comprende al menos un aminoacido seleccionado de Glu48, Asp51, His70, His72, Lys109 e His110. Tambien, se refiere a metodos para producir los anticuerpos que comprenden el cultivo de una celula hospedera con un acido nucleico que los codifica, y la inmunizacion de un animal contra un polipeptido que comprende el dominio MG1-MG2 de la cadena beta (SEQ ID NO: 40) de C5. Ademas, refiere a un articulo de manufactura que contiene una formulacion farmaceutica a base de un anticuerpo anti-C5 y un tampon farmaceuticamente aceptable seleccionado de agua bacteriostatica para inyeccion (BWFI) tamponada con fosfato solucion salina, solucion de Ringer y solucion de dextrosa, para su uso como medicamento.
PE2023002969A 2016-06-17 2017-06-16 Anticuerpos anti-c5 y metodos de uso PE20240825A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Publications (1)

Publication Number Publication Date
PE20240825A1 true PE20240825A1 (es) 2024-04-18

Family

ID=59969459

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023002969A PE20240825A1 (es) 2016-06-17 2017-06-16 Anticuerpos anti-c5 y metodos de uso
PE2018003148A PE20190394A1 (es) 2016-06-17 2017-06-16 Anticuerpos anti-c5 y metodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018003148A PE20190394A1 (es) 2016-06-17 2017-06-16 Anticuerpos anti-c5 y metodos de uso

Country Status (19)

Country Link
EP (1) EP3472316A4 (es)
JP (4) JP6202774B1 (es)
KR (2) KR101852739B1 (es)
CN (3) CN115960223A (es)
AU (1) AU2017285763B2 (es)
BR (1) BR112018075688A2 (es)
CA (1) CA3021956A1 (es)
CL (1) CL2018003573A1 (es)
CR (1) CR20190013A (es)
EA (1) EA201990018A1 (es)
IL (2) IL300611A (es)
MX (2) MX2018015030A (es)
MY (1) MY187848A (es)
PE (2) PE20240825A1 (es)
PH (1) PH12018502354B1 (es)
SG (2) SG11201705584VA (es)
TW (5) TWI610941B (es)
UA (1) UA126561C2 (es)
WO (1) WO2017217524A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
TWI610941B (zh) * 2016-06-17 2018-01-11 Chugai Seiyaku Kabushiki Kaisha 抗ｃ５抗體及使用方法
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
CA3078362A1 (en) * 2017-10-04 2019-04-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
BR112021004141A2 (pt) * 2018-09-06 2021-05-25 The Trustees Of The University Of Pennsylvania anticorpo dependente de ph que se liga especificamente a c5 humano, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, célula, e, animal não humano geneticamente modificado.
WO2020219922A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
WO2022012606A1 (en) * 2020-07-15 2022-01-20 Biosion Inc. Antibodies binding c5 and uses thereof
EP4267612A4 (en) * 2020-12-25 2024-09-04 The Trustees of the University of Pennsylvania HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND THEIR USES

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (es) 1985-07-08 1990-08-21
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4643139B2 (ja) 2001-06-12 2011-03-02 テレフオンアクチーボラゲット エル エム エリクソン（パブル） Ｕｍｔｓ地上無線アクセスネットワーク（ｕｔｒａｎ）での同期
CN101387646B (zh) 2001-08-17 2016-08-10 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
JP4333939B2 (ja) 2001-08-27 2009-09-16 ロード・コーポレーション トロリ線の吊架装置
DE10253331A1 (de) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (ko) 2007-03-20 2008-07-29 (주)화도 폴리에틸렌 관
BRPI0809105A2 (pt) * 2007-03-22 2019-09-10 Novartis Ag antígenos c5 e uso destes
US8420298B2 (en) 2007-04-11 2013-04-16 Sekisui Chemical Co., Ltd. Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin
EP2708559B1 (en) * 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
SG10201405377XA (en) * 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
KR20100054403A (ko) 2008-11-14 2010-05-25 삼성전자주식회사 온라인 공동 작문 장치 및 방법
EP2545079A2 (en) * 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20110111007A (ko) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko) 2010-05-03 2011-11-09 황보철종 매장 포인트 통합 관리 시스템 및 그 방법
JP6309521B2 (ja) * 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
CN105143261B (zh) * 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
JP6505079B2 (ja) * 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
ES2899894T3 (es) * 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
EP3390442B1 (en) * 2015-12-18 2023-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
TWI610941B (zh) * 2016-06-17 2018-01-11 Chugai Seiyaku Kabushiki Kaisha 抗ｃ５抗體及使用方法

Also Published As

Publication number Publication date
JP2024102181A (ja) 2024-07-30
CR20190013A (es) 2019-03-05
CN109312326A (zh) 2019-02-05
WO2017217524A1 (en) 2017-12-21
JP7032077B2 (ja) 2022-03-08
NZ748003A (en) 2024-12-20
TW202239766A (zh) 2022-10-16
MY187848A (en) 2021-10-26
KR102226975B1 (ko) 2021-03-11
AU2017285763B2 (en) 2024-02-01
TW201808996A (zh) 2018-03-16
MX2018015030A (es) 2019-04-22
JP6202774B1 (ja) 2017-09-27
TW202532438A (zh) 2025-08-16
UA126561C2 (uk) 2022-11-02
TW202337903A (zh) 2023-10-01
PH12018502354A1 (en) 2019-09-23
CN115925922A (zh) 2023-04-07
SG10201800265UA (en) 2018-02-27
IL263657B1 (en) 2025-08-01
IL263657B2 (en) 2025-12-01
JP2022091748A (ja) 2022-06-21
TWI807666B (zh) 2023-07-01
PE20190394A1 (es) 2019-03-13
TWI610941B (zh) 2018-01-11
AU2017285763A1 (en) 2018-11-08
IL300611A (en) 2023-04-01
RU2019100222A3 (es) 2020-11-05
JP2017226655A (ja) 2017-12-28
EA201990018A1 (ru) 2019-08-30
KR20190009273A (ko) 2019-01-28
CN115960223A (zh) 2023-04-14
EP3472316A4 (en) 2020-01-08
KR101852739B1 (ko) 2018-04-30
CL2018003573A1 (es) 2019-02-01
CN109312326B (zh) 2022-09-09
EP3472316A1 (en) 2019-04-24
JP2018009021A (ja) 2018-01-18
TWI789369B (zh) 2023-01-11
MX2023001360A (es) 2023-02-27
PH12018502354B1 (en) 2024-02-23
CA3021956A1 (en) 2017-12-21
IL263657A (en) 2019-01-31
RU2019100222A (ru) 2020-07-17
SG11201705584VA (en) 2018-05-30
TW201809000A (zh) 2018-03-16
BR112018075688A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
PE20240825A1 (es) Anticuerpos anti-c5 y metodos de uso
CO2021006092A2 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
AR103162A1 (es) Anticuerpos anti-c5 y métodos para su uso
PE20220708A1 (es) Anticuerpos anti-cd73
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
BR112018009067A8 (pt) anticorpos anti-c5 e métodos de uso
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
AR092216A1 (es) Formulaciones estables de anticuerpos contra tslp
MX2021010951A (es) Composición líquida que comprende un anticuerpo del receptor alfa de interleucina-4 humano.
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
BR112014020019A8 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
PE20180741A1 (es) Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
ES2616258T3 (es) Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
CL2018000131A1 (es) Inmunoconjugados de il22
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
MX2021015501A (es) Anticuerpos y metodos de uso.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof